New Cryoprotectants Outperform DMSO for Preserving Stem Cells
Amino acid-based mixtures rival or beat the gold standard for stem cell cryopreservation, potentially improving clinical outcomes.
Summary
Storing stem cells long-term requires cryoprotective agents (CPAs), but the current standard, DMSO, is toxic and often ineffective. Researchers at RMIT University screened seven novel CPAs derived from deep eutectic solvents, testing them on standard cell lines before applying them to human mesenchymal stem cells. Mixtures of proline with glycerol or ethylene glycol, and alanine with glycerol, matched or exceeded DMSO in cell recovery rates. These findings suggest a safer, more effective class of cryoprotectants that could improve stem cell banking and expand clinical applications in regenerative medicine and longevity-related therapies.
Detailed Summary
Long-term preservation of stem cells is a foundational challenge in regenerative medicine and cell-based therapies. Without effective cryopreservation, stem cells cannot be banked reliably for future clinical use, limiting their therapeutic potential in aging-related diseases and tissue repair.
The current standard cryoprotective agents, dimethylsulfoxide (DMSO) and glycerol, present significant problems. DMSO in particular carries cytotoxic risks, can cause adverse reactions when infused into patients, and delivers poor recovery rates for many cell types, especially stem cells. A better solution has long been sought.
Researchers at RMIT University in Melbourne screened seven novel CPAs broadly based on deep eutectic solvents (DESs) — low-melting mixtures often formed from natural compounds. They first assessed toxicity and membrane permeability in two standard cell lines (THP-1 and HaCaT) to narrow the candidates, then tested the most promising formulations on human mesenchymal stem cells (MSCs), a cell type critical for regenerative applications.
Three CPA mixtures stood out: proline combined with glycerol, proline combined with ethylene glycol, and alanine combined with glycerol. All three achieved cell recovery rates equal to or greater than DMSO-based protocols. Because proline and alanine are naturally occurring amino acids, these formulations are expected to carry a more favorable safety profile than DMSO.
The implications are significant. Improved cryopreservation could expand MSC banking, make stem cell therapies more accessible, and reduce the clinical risks currently associated with residual DMSO in transplanted cells. Caveats include a focus on in vitro recovery metrics only; functional potency, differentiation capacity, and long-term in vivo outcomes were not evaluated. Larger-scale validation and regulatory review will be needed before clinical adoption.
Key Findings
- Proline-glycerol, proline-ethylene glycol, and alanine-glycerol mixtures matched or exceeded DMSO in MSC recovery.
- Seven deep eutectic solvent-based CPAs were screened for toxicity and permeability before stem cell testing.
- Novel CPAs are derived from natural amino acids, suggesting a potentially safer toxicity profile than DMSO.
- Human mesenchymal stem cells, critical for regenerative medicine, were the primary clinical target of this study.
- Findings open a new class of cryoprotectants that could improve stem cell banking for clinical use.
Methodology
Researchers screened seven DES-based CPAs for cytotoxicity and membrane permeability in THP-1 and HaCaT cell lines, then applied lead candidates to human mesenchymal stem cells. Cell recovery post-thaw was compared against DMSO as the gold standard control. The study was conducted in vitro at RMIT University in Melbourne.
Study Limitations
The study measured cell recovery rates in vitro but did not assess post-thaw functional potency, differentiation capacity, or in vivo therapeutic efficacy. Only human MSCs were tested; generalizability to other stem cell types such as hematopoietic or pluripotent stem cells remains unconfirmed. Clinical translation will require regulatory evaluation and larger-scale validation studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.